9th Oct 2014 08:30
LONDON (Alliance News) - Cyprotex PLC Thursday said it has expanded its in-house drug transporter services, and can now offer a full range of in vitro drug transporter assays that are recommended by the regulatory authorities.
The contract research organisation has recently bought two transport services, and got a permit to store, handle and dispose of radiolabelled material which is essential for the transporter services.
Industry knowledge of drug transporters and how they influence drug interactions is growing rapidly. New regulatory guidance released by the US Food and Drug Administration and European Medicines Agency in 2012, as well as a publication by the International Transporter Consortium in 2013, is guiding the future direction in this field.
The regulatory authorities recommend screening those transporters which play a key role in potential clinical drug interactions using in vitro cell based assays. A range of transporters have now been implicated in clinical drug-drug interactions, and this range will continue to expand as new research is published, Cyprotex said.
"We will ensure that our range of assays in this area will continue to expand in line with regulatory guidance and customer demand," Chief Executive Anthony Baxter said in a statement.
Cyprotex shares were down 2.1% at 46.00 pence Thursday morning.
By Steve McGrath; [email protected]; @stevemcgrath1
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
CRX.L